Anticonvulsive effects of the dopamine agonist lisuride maleate after experimental traumatic brain injury

Neuroscience Letters

Volumn 470, Issue 2, 2010, Pages 150-154

  Zweckberger, Klaus ^a   Simunovic, Filip ^a   Kiening, Karl L ^a   Unterberg, Andreas W ^a   Sakowitz, Oliver W ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Controlled cortical impact injury (CCII); Hypotension; Lisuride; Post traumatic epileptic seizures; Secondary brain damage

Indexed keywords

LISURIDE MALEATE; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; BRAIN CONTUSION; BRAIN EDEMA; BRAIN TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; ELECTROENCEPHALOGRAM; HYPOTENSION; INTRACRANIAL PRESSURE; LOADING DRUG DOSE; MALE; MEAN ARTERIAL PRESSURE; NEUROLOGIC EXAMINATION; NEUROPHYSIOLOGY; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSMOTIC PUMP; PRIORITY JOURNAL; RAT; SEIZURE; TRAUMATIC BRAIN INJURY;

ANIMALS; ANTICONVULSANTS; BLOOD PRESSURE; BRAIN; BRAIN INJURIES; DOPAMINE AGONISTS; EDEMA; ELECTROENCEPHALOGRAPHY; INTRACRANIAL PRESSURE; LISURIDE; MAGNETIC RESONANCE IMAGING; MALE; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SEIZURES; TIME FACTORS;

EID: 74449084432     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2009.12.075     Document Type: Article

References (42)

1. Baronti F., Mouradian M.M., Davis T.L., Giuffra M., Brughitta G., Conant K.E., and Chase T.N. Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease. Ann. Neurol. 32 (1992) 776-781
2. Cardwell M., Reymann J.M., Allain H., Leonard B.E., and Bentue-Ferrer D. Lisuride prevents learning and memory impairment and attenuates the increase in extracellular dopamine induced by transient global cerebral ischemia in rats. Brain Res. 771 (1997)
3. Cardwell M., Reymann J.M., Bentue-Ferrer D., Allain H., and Leonard B.E. The dopamine agonists lisuride and piribedil protect against behavioural and histological changes following 4-vessel occlusion in the rat. Neurophysiobiology 34 (1996) 117-124
4. Carruba M.O., Ricciardi S., Negreanu J., Calogero M., and Mantegazza P. Effects of lisuride on body temperature of rats and rabbits: relation to microsomal biotransformation and dopaminergic receptor stimulation. Psychopharmacology (Berl) 70 (1980) 223-229
5. Chase T.N., Baronti F., Fabbrini G., Heuser I.J., Juncos J.L., and Mouradian M.M. Rationale for continuous dopaminomimetic therapy of Parkinson's disease. Neurology 39 (1989) 7-10 discussion 19
6. D'Ambrosio R., Fairbanks J.P., Fender J.S., Born D.E., Doyle D.L., and Miller J.W. Post-traumatic epilepsy following fluid percussion injury in the rat. Brain 127 (2004) 304-314
7. da Silva A.M., Nunes B., Vaz A.R., and Mendonca D. Posttraumatic epilepsy in civilians: clinical and electroencephalographic studies. Acta Neurochir. Suppl. (Wien) 55 (1992) 56-63
8. DeVito W.J., Avakian C., Stone S., Okulicz W.C., Tang K.T., and Shamgochian M. Prolactin induced expression of interleukin-1 alpha, tumor necrosis factor-alpha, and transforming growth factor-alpha in cultured astrocytes. J. Cell. Biochem. 57 (1995) 290-298
9. DeVito W.J., Stone S., and Shamgochian M. Prolactin induced expression of glial fibrillary acidic protein and tumor necrosis factor-alpha at a wound site in the rat brain. Mol. Cell. Endocrinol. 108 (1995) 125-130
10. Diaz-Arrastia R., Agostini M.A., Madden C.J., and Van Ness P.C. Posttraumatic epilepsy: the endophenotypes of a human model of epileptogenesis. Epilepsia 50 Suppl. 2 (2009) 14-20
11. Double K.L., Halliday G.M., Henderson J., Griffiths F.M., Heinemann T., Riederer P., and Gerlach M. The dopamine receptor agonist lisuride attenuates iron-mediated dopaminergic neurodegeneration. Exp. Neurol. 184 (2003) 530-535
12. Enriquez P., and Bullock R. Molecular and cellular mechanisms in the pathophysiology of severe head injury. Curr. Pharm. Des. 10 (2004) 2131-2143
13. Farjo I.B., and McQueen J.K. Dopamine agonists and cobalt-induced epilepsy in the rat. Br. J. Pharmacol. 67 (1979) 353-360
14. Frey L.C. Epidemiology of posttraumatic epilepsy: a critical review. Epilepsia 44 Suppl. 10 (2003) 11-17
15. Fricker A.D., Rios C., Devi L.A., and Gomes I. Serotonin receptor activation leads to neurite outgrowth and neuronal survival. Brain Res. Mol. Brain Res. 138 (2005) 228-235
16. Gaetz M. The neurophysiology of brain injury. Clin. Neurophysiol. 115 (2004) 4-18
17. Gille G., Rausch W.D., Hung S.T., Moldzio R., Ngyuen A., Janetzky B., Engfer A., and Reichmann H. Protection of dopaminergic neurons in primary culture by lisuride. J. Neural Transm. 109 (2002) 157-169
18. Grande P.O., Asgeirsson B., and Nordstrom C.H. Physiologic principles for volume regulation of a tissue enclosed in a rigid shell with application to the injured brain. J. Trauma 42 (1997) S23-31
19. Harkany T., Mulder J., Horvath K.M., Keijser J., van der Meeberg E.K., Nyakas C., and Luiten P.G. Oral post-lesion administration of 5-HT(1A) receptor agonist repinotan hydrochloride (BAY × 3702) attenuates NMDA-induced delayed neuronal death in rat magnocellular nucleus basalis. Neuroscience 108 (2001) 629-642
20. Horowski R. Hypothermic action of lisuride in rats and differences to bromocriptine in the antagonistic effect of neuroleptics. Naunyn Schmiedebergs Arch. Pharmacol. 306 (1979) 147-151
21. Horowski R., Marsden C.D., and Obeso J.A. Continuous dopaminergic stimulation: state of the art and outlook. J. Neural. Transm. Suppl. 27 (1988) 249-252
22. Hunt R.F., Scheff S.W., and Smith B.N. Posttraumatic epilepsy after controlled cortical impact injury in mice. Exp. Neurol. 215 (2009) 243-252
23. Itil T.M., Herrmann W.M., and Akpinar S. Prediction of psychotropic properties of lisuride hydrogen maleate by quantitative pharmaco-electroencephalogram. Int. J. Clin. Pharmacol. Biopharm. 12 (1975) 221-233
24. Jankovic J., and Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson's disease. CNS Drugs 21 (2007) 677-692
25. Johnson K.W., Nelson D.L., Dieckman D.K., Wainscott D.B., Lucaites V.L., Audia J.E., Owton W.M., and Phebus L.A. Neurogenic dural protein extravasation induced by meta-chlorophenylpiperazine (mCPP) involves nitric oxide and 5-HT2B receptor activation. Cephalalgia 23 (2003) 117-123
26. Kline A.E., Yu J., Horvath E., Marion D.W., and Dixon C.E. The selective 5-HT(1A) receptor agonist repinotan HCl attenuates histopathology and spatial learning deficits following traumatic brain injury in rats. Neuroscience 106 (2001) 547-555
27. Kotecha S.A., Oak J.N., Jackson M.F., Perez Y., Orser B.A., Van Tol H.H., and MacDonald J.F. A D2 class dopamine receptor transactivates a receptor tyrosine kinase to inhibit NMDA receptor transmission. Neuron 35 (2002) 1111-1122
28. Kroppenstedt S.N., Kern M., Thomale U.W., Schneider G.H., Lanksch W.R., and Unterberg A.W. Effect of cerebral perfusion pressure on contusion volume following impact injury. J. Neurosurg. 90 (1999) 520-526
29. Micieli G., Martignoni E., Cavallini A., Pacchetti C., Rossi F., Horowski R., and Nappi G. Lisuride and bromocryptine in l-Dopa stable-responder parkinsonian patients: a comparative, double-blind evaluation of cardiopressor and neurochemical effects. Funct. Neurol. 11 (1996) 317-325
30. Miyazawa T., Murayama C., and Nakagawa H. Effect of lisuride on experimental cerebral infarction in rats. Nippon Yakurigaku Zasshi 98 (1991) 449-456
31. Nobuhara K. A quantitative pharmaco-EEG study on psychotropic properties of cerebral metabolic enhancers: comparison between young and elderly healthy volunteers. Seishin Shinkeigaku Zasshi 95 (1993) 392-416
32. Nordstrom C.H. Assessment of the optimal cerebral perfusion pressure in head-injured patients. Anesth. Analg. 101 (2005) 299-300 author reply 300
33. Nordstrom C.H. The Lund concept: is this logical?. Acta Neurochir. Suppl. 95 (2005) 475-480
34. Nordstrom C.H. Physiological and biochemical principles underlying volume-targeted therapy-the "Lund concept". Neurocrit. Care 2 (2005) 83-95
35. Nordstrom C.H. Volume-targeted therapy of increased intracranial pressure. Acta Neurochir. Suppl. 86 (2003) 355-360
36. Nortje J., and Menon D.K. Traumatic brain injury: physiology, mechanisms, and outcome. Curr. Opin. Neurol. 17 (2004) 711-718
37. O'Neill M.J., Hicks C.A., Ward M.A., Cardwell G.P., Reymann J.M., Allain H., and Bentue-Ferrer D. Dopamine D2 receptor agonists protect against ischaemia-induced hippocampal neurodegeneration in global cerebral ischaemia. Eur. J. Pharmacol. 352 (1998) 37-46
38. Oosterink B.J., Korte S.M., Nyakas C., Korf J., and Luiten P.G. Neuroprotection against N-methyl-D-aspartate-induced excitotoxicity in rat magnocellular nucleus basalis by the 5-HT1A receptor agonist 8-OH-DPAT. Eur. J. Pharmacol. 358 (1998) 147-152
39. Sakowitz O.W., Unterberg A.W., and Stover J.F. Neuronal activity determined by quantitative EEG and cortical microdialysis is increased following controlled cortical impact injury in rats. Acta Neurochir. Suppl. 81 (2002) 221-223
40. Stracke H., Heinlein W., Horowski R., and Schatz H. Dopamine agonists in the treatment of hyperprolactinemia. Comparison between bromocriptine and lisuride. Arzneimittelforschung 36 (1986) 1834-1836
41. Wang X., Zhong P., Gu Z., and Yan Z. Regulation of NMDA receptors by dopamine D4 signaling in prefrontal cortex. J. Neurosci. 23 (2003) 9852-9861
42. Zweckberger K., Eros C., Zimmermann R., Kim S.W., Engel D., and Plesnila N. Effect of early and delayed decompressive craniectomy on secondary brain damage after controlled cortical impact in mice. J. Neurotrauma 23 (2006) 1083-1093